Spruce Biosciences develops therapies for neurological disorders, led by an enzyme replacement therapy for a rare genetic brain disease. It last closed at $40.49 on Nov 17, down 4.17% on the day.
Only 1 firm rated SPRB in the past 90 days, not enough for a consensus
Average 12-month target
$149.00
▲ 268.0% upside
Based on 1 analyst who set a price target on SPRB in the past 90 days. The average target is $149.00, with a high of $149.00 and a low of $149.00, compared with the last close of $40.49.
Low $149.00Avg $149.00High $149.00
Blue marker: last close $40.49
Highest target$149.00
Average target$149.00
Lowest target$149.00
Latest rating changes
Lake StreetInitiated
Sep 17Buy$149
GuggenheimTarget lowered
Aug 17Buy$123 → $104
CitizensMaintained
Aug 13Buy$144
B. Riley SecuritiesInitiated
Jul 13Buy$160
GuggenheimInitiated
Jun 16Buy$123
Date
Firm
Action
Rating
Price target
Sep 17
Lake Street
Initiated
Buy
$149
Aug 17
Guggenheim
Target lowered
Buy
$123 → $104
Aug 13
Citizens
Maintained
Buy
$144
Jul 13
B. Riley Securities
Initiated
Buy
$160
Jun 16
Guggenheim
Initiated
Buy
$123
Loading…
Technical Analysis
SPRB · as of the Nov 17 close · updated after every close
Downtrend
The stock is 11% below its 20 day and 15% below its 50 day average. It is 33% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the swing low (Jul 28) at $40.33, and the nearest resistance the Pivot at $40.76.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 8.3%/day
Key levels
$127.9052 week high+215.9%
$53.70200 day average+32.6%
$48.48100 day average+19.7%
$46.5450 day average+14.9%
$45.51Swing high (Jul 27)+12.4%
$44.9020 day average+10.9%
$41.54Pivot R1+2.6%
$40.76Pivot+0.7%
$40.49Last close
$40.33Swing low (Jul 28)−0.4%
$39.71Pivot S1−1.9%
$38.0652 week low−6.0%
Indicators
RSI (14)
40.87
Middle of its range
Neutral
MACD
-0.80
Below its signal line
Bearish
Stochastic
12.6
Near the bottom of its range
Oversold
ADX (14)
15.2
No clear trend
Williams %R
-95.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-188.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−5.4%
Change over 10 sessions
Bearish
ATR (14)
$3.38
Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 19.4%/day
Key levels
$127.9052 week high+215.9%
$53.70200 day average+32.6%
$48.48100 day average+19.7%
$46.5450 day average+14.9%
$45.51Swing high (Jul 27)+12.4%
$44.9020 day average+10.9%
$41.54Pivot R1+2.6%
$40.76Pivot+0.7%
$40.49Last close
$40.33Swing low (Jul 28)−0.4%
$39.71Pivot S1−1.9%
$38.0652 week low−6.0%
Indicators
RSI (14)
39.91
Weak, oversold below 30
Neutral
MACD
-3.52
Below its signal line
Bearish
Stochastic
20.4
Middle of its range
Neutral
ADX (14)
10.0
No clear trend
Williams %R
-90.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-94.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−24.6%
Change over 10 sessions
Bearish
ATR (14)
$7.87
Typical daily range, 19.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SPRB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow SPRB usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SPRB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRB is in one of them and how their past SPRB trades turned out.
Spruce Biosciences is a biopharmaceutical company that develops therapies for neurological disorders. Its lead product candidate, TA-ERT, is an enzyme replacement therapy under development for MPS IIIB, a rare genetic disease that causes progressive brain damage and has no approved treatments. The therapy is designed to be delivered directly into the central nervous system, and its intended customers are patients with the disease and the clinicians who treat them. The company is based in South San Francisco, California.